|
|
|
|
|
|
Sponsors and Collaborators: |
University Hospital Freiburg Hoffmann-La Roche |
Information provided by: | University Hospital Freiburg |
ClinicalTrials.gov Identifier: | NCT00411515 |
The purpose of this prospectively randomized multicentre study was to prove the efficacy and safety of mycophenolate mofetil (MMF) to preventing graft rejection and improvement of clear graft survival following high-risk keratoplasty.
The patients of the MMF group receive MMF orally 2x1 g daily for 6 months. Endpoints were immune reaction free and clear graft survival and the occurence of side-effects.
Condition | Intervention | Phase |
Corneal Transplantation |
Drug: Mycophenolate Mofetil 2x 1g |
Phase IV |
ChemIDplus related topics: | Mycophenolate Mofetil Mycophenolate mofetil hydrochloride |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Germany | |||||
University Eye hospital | |||||
Freiburg, Germany, 79106 |
University Hospital Freiburg |
Hoffmann-La Roche |
Study Chair: | Thomas Reinhard, Prof. MD | University eye hospital Freiburg |
Study ID Numbers: | FR-2000-05-2006-06 |
First Received: | December 12, 2006 |
Last Updated: | December 14, 2006 |
ClinicalTrials.gov Identifier: | NCT00411515 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
|
|